Tag Archives: drug-eluting balloons

Reestenosis de bordes con stents liberadores de everolimus

Arterial Patency in Femoropopliteal Disease with Drug-Eluting Balloons

Arterial Patency in Femoropopliteal Disease with Drug-Eluting Balloons

Follow-up of drug-coated balloon angioplasty in femoropopliteal disease in a real-world population. Using drug-releasing devices has decreased the rate of restenosis in obstructive femoropopliteal lesions compared with conventional balloons or conventional stents (bare-nitinol stent, BNS). Both in the placement of BNS and of drug-eluting stents (DES) there is a mechanical risk of stent fracture or


The New Sirolimus Eluting Balloons Are Also Effective

The technological development of drug eluting stents has allowed us to treat increasingly complex patients, with around 10% stenosis and using more, and longer stents.  This situation generates a great challenge: keep using stents or use paclitaxel coated balloons (PCB). At present, there are sirolimus drug coated balloons (SCB), but we do not have enough

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

Should We Start Stenting with DES in Femoropopliteal Territory?

Percutaneous intervention of femoropopliteal lesions have been the standard strategy these past two decades. The development of drug eluting stents (DES) or drug eluting balloons (DEB) has improved patency rate compared against conventional balloon angioplasty. The ILLUMINA -a multicenter study- looked into the polymer free self-expanding stent NiTiDES, which showed at 1 year an 87%

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

Drug-Eluting Balloons Find Their Niche

According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat in-stent restenosis. Drug-eluting balloons seem to work equally well for the treatment of long-term in-stent restenosis compared with new stent implantation (for the thin-strut DES registry). If DEBs can compete with DES—adding to the advantage of avoiding a

Diferentes técnicas para mejorar los resultados en claudicación intermitente

Different Techniques for the Improvement of Outcomes in Intermittent Claudication

Peripheral vascular diseases affect over 20% of the population and can affect up to 30% of people with cardiovascular risk factors. The most important treatment points include modification of risk factors, exercise, optimal medical treatment, and timely revascularization.   Given its lower risk of peri-procedural complications (when compared to surgery), endovascular therapy is generally the first

Promising outcomes for DEB in long femoropopliteal artery lesions

Courtesy of Dr. Carlos Fava. For type A and B femoropopliteal artery lesions, percutaneous transluminal angioplasty (PTA) with balloon has proven beneficial; however, drug-eluting balloons (DEB) have shown superiority as regards restenosis.   Some studies have reported favorable outcomes for DEB in type C and D lesions, but its real benefit is still unclear.   This study prospectively